Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | BRD2 | P25440 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195280 | 0.86 | NPC1 (0.38) | CREBBPBRD4BRD2KMT2AMEN1 | |
| SCHEMBL1195294 | 0.84 | BRD4 (0.49) | CREBBPBRD4BRD2KMT2AMEN1 | |
| SCHEMBL1195163 | 0.83 | GSK3B (0.41) | KMT2AMEN1ALDH1A1TSHRPARP10 | |
| SCHEMBL1194457 | 0.83 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1KDM4EMAOB | |
| SCHEMBL1190292 | 0.83 | LMNA (0.44) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL9701615 | 0.82 | KMT2A (0.59) | CREBBPBRD4BRD2KMT2AMEN1 | |
| SCHEMBL1205449 | 0.82 | L3MBTL1 (0.41) | KMT2AMEN1ALDH1A1MAOBNPC1 | |
| SCHEMBL1194335 | 0.81 | PTGS2 (0.35) | CREBBPBRD4BRD2KMT2AMEN1 | |
| SCHEMBL1194738 | 0.80 | MLYCD (0.39) | CREBBPBRD4BRD2KMT2AMEN1 | |
| SCHEMBL13760629 | 0.80 | NPC1 (0.35) | CREBBPBRD4BRD2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| EP-2242740-B1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-12-12 | — | — | EP | disclosed |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2012-01-12 | — | — | US | disclosed |
| US-8076336-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-8076336-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097972-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | CREBBP 4461/4885BRD4 655/4885BRD2 2400/4885 |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | CREBBP 4461/4885BRD4 655/4885BRD2 2400/4885 |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL1, F2RL3 | CREBBP 4719/4885BRD4 1720/4885BRD2 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.